Monoclonal antibody techniques. 50 years of development
暂无分享,去创建一个
D. A. Yakovleva | D. Dmitriev | Y. Tarakanova | A. Pechelyulko | Yulia S. Massino | Olga L. Segal | Maria V. Lichutina | Alexander D Dmitriev
[1] I. Martínez,et al. Production and characterization of monoclonal antibodies for the detection of the hepatitis C core antigen , 2023, Frontiers in molecular biosciences.
[2] Yang Zhang. Evolution of phage display libraries for therapeutic antibody discovery , 2023, mAbs.
[3] N. Austriaco. Yeast oral vaccines against infectious diseases , 2023, Frontiers in Microbiology.
[4] Atsumi Sakaguchi,et al. Rapid, simple, and effective strategy to produce monoclonal antibodies targeting protein structures using hybridoma technology , 2023, Journal of Biological Engineering.
[5] K. Schuebel,et al. Convergent antibody responses are associated with broad neutralization of hepatitis C virus , 2023, Frontiers in Immunology.
[6] V. Srivastava,et al. Yeast-Based Virus-like Particles as an Emerging Platform for Vaccine Development and Delivery , 2023, Vaccines.
[7] A. Buisman,et al. A synthetic human 3D in vitro lymphoid model enhancing B-cell survival and functional differentiation , 2022, iScience.
[8] A. C. de Freitas,et al. Standardization and Key Aspects of the Development of Whole Yeast Cell Vaccines , 2022, Pharmaceutics.
[9] A. K. Ryabko,et al. Optimization of Electrofusion Parameters for Producing Hybridomas Synthesizing Human Monoclonal Antibodies , 2022, Biotekhnologiya.
[10] M. Imamura,et al. Patient-derived monoclonal antibody neutralizes HCV infection in vitro and vivo without generating escape mutants , 2022, PloS one.
[11] P. Dalby,et al. The global landscape of approved antibody therapies , 2022, Antibody therapeutics.
[12] G. Pantaleo,et al. Antibodies to combat viral infections: development strategies and progress , 2022, Nature Reviews Drug Discovery.
[13] T. Yasui,et al. Monoclonal antibody therapeutics for infectious diseases: Beyond normal human immunoglobulin , 2022, Pharmacology & Therapeutics.
[14] Oliver J. Dressler,et al. High-throughput single-cell antibody secretion quantification and enrichment using droplet microfluidics-based FRET assay , 2022, iScience.
[15] Y. Sado,et al. An improved iliac lymph node method for production of monoclonal antibodies , 2021, Development, growth & differentiation.
[16] M. Tomita,et al. Class-Switching of B Lymphocytes by DNA and Cell Immunization for Stereospecific Monoclonal Antibodies against Native GPCR , 2021, Immuno.
[17] A. Oxenius,et al. Single B cell technologies for monoclonal antibody discovery. , 2021, Trends in immunology.
[18] S. Pambudi,et al. Humoral and cellular immunity in mice immunized with whole recombinant yeast expressing complex NS2B/NS3 protein of dengue serotype 3 , 2021, IOP Conference Series: Earth and Environmental Science.
[19] Elena Ivanova. Yeasts in nanotechnology-enabled oral vaccine and gene delivery , 2021, Bioengineered.
[20] A. H. Laustsen,et al. Animal Immunization, in Vitro Display Technologies, and Machine Learning for Antibody Discovery. , 2021, Trends in biotechnology.
[21] S. Krah,et al. Antibody display technologies: selecting the cream of the crop , 2021, Biological chemistry.
[22] R. Aguiar,et al. Hybridoma technology: is it still useful? , 2021, Current research in immunology.
[23] A. Solonin,et al. A simple method to purify recombinant HCV core protein expressed in Pichia pastoris for obtaining virus-like particles and producing monoclonal antibodies. , 2021, Protein expression and purification.
[24] Aaron M. Seese,et al. Generation of a cost-effective cell line for support of high-throughput isolation of primary human B cells and monoclonal neutralizing antibodies , 2020, Journal of Immunological Methods.
[25] C. Sharma,et al. Hybridoma technology a versatile method for isolation of monoclonal antibodies, its applicability across species, limitations, advancement and future perspectives , 2020, International Immunopharmacology.
[26] R. Rappuoli,et al. Editorial: Reverse Vaccinology , 2019, Front. Immunol..
[27] В. Н. Каркищенко,et al. ТРАНСГЕННЫЕ И НОКАУТНЫЕ КРОЛИКИ В БИОМЕДИЦИНЕ И ГЕНОТЕРАПИИ. CRISPR/CAS9-ТЕХНОЛОГИИ (ОБЗОР) , 2019 .
[28] Yu. N. Tarakanova,et al. Твердофазный иммуноферментный анализ: история, теория и практическое использование , 2019 .
[29] Piyush Kumar,et al. Yeast-based vaccines: New perspective in vaccine development and application. , 2019, FEMS yeast research.
[30] E. Kashuba,et al. The Immunogenicity in Mice of HCV Core Delivered as DNA Is Modulated by Its Capacity to Induce Oxidative Stress and Oxidative Stress Response , 2019, Cells.
[31] Eleanor Barnes,et al. Approaches, Progress, and Challenges to Hepatitis C Vaccine Development , 2019, Gastroenterology.
[32] Виталий Васильевич Зверев,et al. РЕКОМБИНАНТНЫЕ АНТИТЕЛА В ПРОТИВОВИРУСНОЙ ТЕРАПИИ: ДОСТИЖЕНИЯ И ПЕРСПЕКТИВЫ , 2018 .
[33] Valerie J Kinchen,et al. Defining Breadth of Hepatitis C Virus Neutralization , 2018, Front. Immunol..
[34] Valerie J Kinchen,et al. Can Broadly Neutralizing Monoclonal Antibodies Lead to a Hepatitis C Virus Vaccine? , 2018, Trends in microbiology.
[35] Y. Jang,et al. Comparative immunogenicity of preparations of yeast-derived dengue oral vaccine candidate , 2018, Microbial Cell Factories.
[36] J. Ball,et al. A novel neutralizing human monoclonal antibody broadly abrogates hepatitis C virus infection in vitro and in vivo , 2017, Antiviral research.
[37] Christoph A Merten,et al. Microfluidic single-cell technology in immunology and antibody screening. , 2017, Molecular aspects of medicine.
[38] H. Kang,et al. Oral vaccination through voluntary consumption of the convict grouper Epinephelus septemfasciatus with yeast producing the capsid protein of red-spotted grouper nervous necrosis virus. , 2017, Veterinary microbiology.
[39] T. Steele. Life begins at forty – hybridomas: ageing technology holds promise for future drug discoveries , 2016 .
[40] S. El-Kafrawy,et al. Monoclonal antibodies: Principles and applications of immmunodiagnosis and immunotherapy for hepatitis C virus. , 2015, World journal of hepatology.
[41] Burak Dura,et al. Deformability-based microfluidic cell pairing and fusion. , 2014, Lab on a chip.
[42] Y. Lee,et al. Oral immunization with whole yeast producing viral capsid antigen provokes a stronger humoral immune response than purified viral capsid antigen , 2014, Letters in applied microbiology.
[43] Simon J. Henderson,et al. Monoclonal antibody therapeutics: history and future. , 2012, Current opinion in pharmacology.
[44] Christoph A. Merten,et al. Functional single-cell hybridoma screening using droplet-based microfluidics , 2012, Proceedings of the National Academy of Sciences.
[45] Andressa Ardiani,et al. Vaccines based on whole recombinant Saccharomyces cerevisiae cells. , 2010, FEMS yeast research.
[46] Andreas Radbruch,et al. Generation of stable monoclonal antibody-producing BCR+ human memory B cells by genetic programming , 2009, Nature Medicine.
[47] A. Tarr,et al. Determination of the human antibody response to the epitope defined by the hepatitis C virus-neutralizing monoclonal antibody AP33. , 2007, The Journal of general virology.
[48] S. Emerson,et al. Human monoclonal antibodies that react with the E2 glycoprotein of hepatitis C virus and possess neutralizing activity , 2005, Hepatology.
[49] Fatıma YÜcel,et al. Development of mouse hybridomas by fusion of myeloma cells with lymphocytes derived from spleen, lymph node, and bone marrow. , 2003, Hybridoma and hybridomics.
[50] A. Prilipov,et al. IL-21/CD40L stimulation of human B-lymphocytes in vitro and their characteristics , 2020 .
[51] G. Winter,et al. Making antibodies by phage display technology. , 1994, Annual review of immunology.